This biotechnology company develops first-in-class biologics targeting the root cause of drug resistance and immune evasion in late-stage diseases. Their lead therapy, CBT300, is designed as a non-toxic monotherapy to reverse resistance mechanisms in recurrent cancers and certain viral infections. The company aims to provide life-saving treatment options where current standards of care have failed.
Funding
$80K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Recurrent and drug-resistant cancers present a significant challenge due to the development of resistance mechanisms and immune evasion, leading to poor survival rates and limited treatment options. Current therapies often fail to address the underlying causes of resistance, resulting in disease recurrence and progression. There is a critical need for novel, non-toxic therapies that can overcome drug resistance and restore immune system function in late-stage cancer patients.
Solution
Creative BioTherapeutics is developing CBT300, a first-in-class biologic designed to target the root causes of drug resistance and immune evasion in recurrent and drug-resistant cancers. CBT300 is a platform monotherapy that reverses drug resistance and promotes immune system activation, leading to tumor regression and improved survival rates. Preclinical studies have demonstrated that CBT300, alone or in combination with standard of care, can eliminate tumors and increase immune cell infiltration without significant toxicity. The therapy targets a novel survival pathway common to multiple cancers and viral diseases, offering a broad application potential.
Target Audience
The primary target audience includes patients with recurrent and drug-resistant cancers, particularly those with metastatic breast cancer, glioblastoma, and pediatric brain cancers, as well as those with late-stage viral infections.
Features
- Targets extracellular GRP78 to reverse drug resistance and immune suppression
- Demonstrated efficacy in preclinical models of breast, brain, lung, colon, melanoma, ovarian, and renal cancers
- Shows significant tumor regression (up to 65% in some models) and improved survival rates (up to 88% in drug-resistant MBC models) in preclinical studies
- Exhibits no observed toxicity in preclinical studies
- Can be used as a monotherapy or in combination with low-dose chemotherapy
- Effective against multiple viruses, including COVID-19, Ebola, and Influenza A in preclinical testing
- Potential application in neurodegenerative diseases like Parkinson's and Alzheimer's